AIMS/HYPOTHESIS: Regulation of glyceroneogenesis and its key enzyme cytosolic phosphoenolpyruvate carboxykinase (PEPCK-C) plays a major role in the control of fatty acid release from adipose tissue. Here we investigate the effect of rosiglitazone on the expression of genes involved in fatty acid metabolism and the resulting metabolic consequences. MATERIALS AND METHODS: Rosiglitazone was administered to Zucker fa/fa rats for 4 days and to 24 diabetic patients for 12 weeks, then mRNA expression for the genes encoding PEPCK-C, mitochondrial PEPCK, adipocyte lipid-binding protein, glycerol kinase, lipoprotein lipase and glycerol-3-phosphate dehydrogenase was examined in s.c. adipose tissue by real-time RT-PCR. Glyceroneogenesis was determined using [1-(14)C]pyruvate incorporation into lipids. Cultured adipose tissue explants from overweight women undergoing plastic surgery were incubated with rosiglitazone for various times before mRNA determination and analysis of PEPCK-C protein, activity and glyceroneogenesis. RESULTS: Rosiglitazone administration to rats induced the expression of the gene encoding PEPCK-C mRNA (PCK1) and PEPCK-C activity in adipose tissue with a resulting 2.5-fold increase in glyceroneogenesis. This was accompanied by an improvement in dyslipidaemia as demonstrated by the decrease in plasma NEFAs and triacylglycerol. In rosiglitazone-treated diabetic patients, PCK1 mRNA was raised 2.5-fold in s.c. adipose tissue. Rosiglitazone treatment of adipose tissue explants from overweight women caused a selective augmentation in PCK1 mRNA which reached a maximum of 9-fold at 14 h, while mRNA for other genes remained unaffected. Experiments with inhibitors showed a direct and transcription-only effect, which was followed by an increase in PEPCK-C protein, enzyme activity and glyceroneogenesis. CONCLUSIONS/ INTERPRETATION: These results favour adipocyte glyceroneogenesis as the initial thiazolidinedione-responsive pathway leading to improvement in dyslipidaemia.
AIMS/HYPOTHESIS: Regulation of glyceroneogenesis and its key enzyme cytosolic phosphoenolpyruvate carboxykinase (PEPCK-C) plays a major role in the control of fatty acid release from adipose tissue. Here we investigate the effect of rosiglitazone on the expression of genes involved in fatty acid metabolism and the resulting metabolic consequences. MATERIALS AND METHODS:Rosiglitazone was administered to Zucker fa/fa rats for 4 days and to 24 diabeticpatients for 12 weeks, then mRNA expression for the genes encoding PEPCK-C, mitochondrial PEPCK, adipocyte lipid-binding protein, glycerol kinase, lipoprotein lipase and glycerol-3-phosphate dehydrogenase was examined in s.c. adipose tissue by real-time RT-PCR. Glyceroneogenesis was determined using [1-(14)C]pyruvate incorporation into lipids. Cultured adipose tissue explants from overweight women undergoing plastic surgery were incubated with rosiglitazone for various times before mRNA determination and analysis of PEPCK-C protein, activity and glyceroneogenesis. RESULTS:Rosiglitazone administration to rats induced the expression of the gene encoding PEPCK-C mRNA (PCK1) and PEPCK-C activity in adipose tissue with a resulting 2.5-fold increase in glyceroneogenesis. This was accompanied by an improvement in dyslipidaemia as demonstrated by the decrease in plasma NEFAs and triacylglycerol. In rosiglitazone-treated diabeticpatients, PCK1 mRNA was raised 2.5-fold in s.c. adipose tissue. Rosiglitazone treatment of adipose tissue explants from overweight women caused a selective augmentation in PCK1 mRNA which reached a maximum of 9-fold at 14 h, while mRNA for other genes remained unaffected. Experiments with inhibitors showed a direct and transcription-only effect, which was followed by an increase in PEPCK-C protein, enzyme activity and glyceroneogenesis. CONCLUSIONS/ INTERPRETATION: These results favour adipocyte glyceroneogenesis as the initial thiazolidinedione-responsive pathway leading to improvement in dyslipidaemia.
Authors: G D Tan; B A Fielding; J M Currie; S M Humphreys; M Désage; K N Frayn; M Laville; H Vidal; F Karpe Journal: Diabetologia Date: 2004-12-24 Impact factor: 10.122
Authors: Jerry L Chen; Erin Peacock; Waheeda Samady; Scott M Turner; Richard A Neese; Marc K Hellerstein; Elizabeth J Murphy Journal: J Biol Chem Date: 2005-05-11 Impact factor: 5.157
Authors: Ulf Risérus; Garry D Tan; Barbara A Fielding; Matt J Neville; Jenny Currie; David B Savage; V Krishna Chatterjee; Keith N Frayn; Stephen O'Rahilly; Fredrik Karpe Journal: Diabetes Date: 2005-05 Impact factor: 9.461
Authors: V Van Harmelen; S Reynisdottir; K Cianflone; E Degerman; J Hoffstedt; K Nilsell; A Sniderman; P Arner Journal: J Biol Chem Date: 1999-06-25 Impact factor: 5.157
Authors: Adam B Mayerson; Ripudaman S Hundal; Sylvie Dufour; Vincent Lebon; Douglas Befroy; Gary W Cline; Staffan Enocksson; Silvio E Inzucchi; Gerald I Shulman; Kitt F Petersen Journal: Diabetes Date: 2002-03 Impact factor: 9.461
Authors: Daozhong Jin; Hong Guo; So Young Bu; Yuanyuan Zhang; Jennifer Hannaford; Douglas G Mashek; Xiaoli Chen Journal: FASEB J Date: 2010-10-25 Impact factor: 5.191
Authors: Melina Claussnitzer; Simon N Dankel; Bernward Klocke; Harald Grallert; Viktoria Glunk; Tea Berulava; Heekyoung Lee; Nikolay Oskolkov; Joao Fadista; Kerstin Ehlers; Simone Wahl; Christoph Hoffmann; Kun Qian; Tina Rönn; Helene Riess; Martina Müller-Nurasyid; Nancy Bretschneider; Timm Schroeder; Thomas Skurk; Bernhard Horsthemke; Derek Spieler; Martin Klingenspor; Martin Seifert; Michael J Kern; Niklas Mejhert; Ingrid Dahlman; Ola Hansson; Stefanie M Hauck; Matthias Blüher; Peter Arner; Leif Groop; Thomas Illig; Karsten Suhre; Yi-Hsiang Hsu; Gunnar Mellgren; Hans Hauner; Helmut Laumen Journal: Cell Date: 2014-01-16 Impact factor: 41.582
Authors: Zhongxiao Wan; Ian Ritchie; Marie-Soleil Beaudoin; Laura Castellani; Catherine B Chan; David C Wright Journal: PLoS One Date: 2012-07-23 Impact factor: 3.240